<?xml version="1.0" encoding="UTF-8"?>
<title-group>
 <article-title>Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study</article-title>
</title-group>
